trending Market Intelligence /marketintelligence/en/news-insights/trending/KxkDR66GvM9dI-DDyio4cA2 content esgSubNav
In This List

Immunotec fiscal Q1 profit falls YOY

Podcast

Next in Tech | Episode 66: Connected vehicles in transition

Blog

Gold - Geopolitical tensions and inflation remain key drivers

Blog

Lithium and Cobalt - Softer demand weighs on prices

Podcast

Street Talk | Episode 94: Recessionary fears in ’22 overblown, Fed could overtighten


Immunotec fiscal Q1 profit falls YOY

Immunotec Inc. said its normalized net income for the fiscal first quarter ended Jan. 31 came to C$345,650, a decrease of 57.7% from C$817,260 in the prior-year period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin declined to 1.5% from 4.6% in the year-earlier period.

Total revenue climbed 28.0% year over year to C$22.9 million from C$17.9 million, and total operating expenses increased 32.0% from the prior-year period to C$22.4 million from C$17.0 million.

Reported net income declined 58.1% on an annual basis to C$346,450, or 0 cents per share, from C$827,270, or 1 cents per share.